| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Net revenue | 236,561 | |||
| Research and development | 11,725 | |||
| General and administrative | 75,113 | |||
| Consulting and professional fees | 398,263 | |||
| Rent | 90,000 | |||
| Total operating expenses | 575,101 | |||
| Loss from operations | -338,540 | |||
| Interest expense | 158,286 | |||
| Interest expense attributable to amortization of discount | 52,148 | |||
| Derivative income (expense) | -675,528 | |||
| Penalties | 50,000 | |||
| Total other income (expense), net | -935,962 | |||
| Net loss before income taxes | -1,274,502 | |||
| Income tax provision | 0 | |||
| Net loss | -1,274,502 | |||
| Net loss per common share, basic | -0.05 | |||
| Net loss per common share, diluted | -0.05 | |||
| Number of weighted average shares - basic | 23,521,970 | |||
| Number of weighted average shares - diluted | 23,521,970 | |||
Regen BioPharma Inc (RGBPP)
Regen BioPharma Inc (RGBPP)